The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period

We describe the immediate- and longer-term direct medical costs of care for individuals diagnosed with HIV at CD4 counts <350/mm3 (“late presenters”). We collected and stratified by initial CD4 count all inpatient, outpatient, and drug costs for all newly diagnosed patients accessing HIV care wit...

Full description

Bibliographic Details
Main Authors: Hartmut B. Krentz, M. John Gill
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:AIDS Research and Treatment
Online Access:http://dx.doi.org/10.1155/2012/757135
id doaj-3d4b2d391afc47a7a5df2ee979b825a2
record_format Article
spelling doaj-3d4b2d391afc47a7a5df2ee979b825a22020-11-24T23:14:49ZengHindawi LimitedAIDS Research and Treatment2090-12402090-12592012-01-01201210.1155/2012/757135757135The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year PeriodHartmut B. Krentz0M. John Gill1Southern Alberta Clinic, Sheldon M Chumir Health Centre, No. 3223, 1213-4th St SW, Calgary, AB, T2R 0X7, CanadaSouthern Alberta Clinic, Sheldon M Chumir Health Centre, No. 3223, 1213-4th St SW, Calgary, AB, T2R 0X7, CanadaWe describe the immediate- and longer-term direct medical costs of care for individuals diagnosed with HIV at CD4 counts <350/mm3 (“late presenters”). We collected and stratified by initial CD4 count all inpatient, outpatient, and drug costs for all newly diagnosed patients accessing HIV care within Southern Alberta from 1/1/1995 to 1/1/2010. 59% of new patients were late presenters. We found significantly higher costs for late presenters, especially inpatient costs, during the first year after accessing care. Direct medical costs remained almost twice as high for late presenters in subsequent years compared to patients presenting with CD4 counts >350/mm3 despite significantly their improved CD4 counts. The sustained high cost for late presenters has implications for recent recommendations for wider routine HIV testing and the earlier initiation of cART. Earlier diagnosis and treatment, while increasing the immediate expenditures within a population, may produce both direct and indirect cost savings in the longer term.http://dx.doi.org/10.1155/2012/757135
collection DOAJ
language English
format Article
sources DOAJ
author Hartmut B. Krentz
M. John Gill
spellingShingle Hartmut B. Krentz
M. John Gill
The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
AIDS Research and Treatment
author_facet Hartmut B. Krentz
M. John Gill
author_sort Hartmut B. Krentz
title The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
title_short The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
title_full The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
title_fullStr The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
title_full_unstemmed The Direct Medical Costs of Late Presentation (<350/mm3) of HIV Infection over a 15-Year Period
title_sort direct medical costs of late presentation (<350/mm3) of hiv infection over a 15-year period
publisher Hindawi Limited
series AIDS Research and Treatment
issn 2090-1240
2090-1259
publishDate 2012-01-01
description We describe the immediate- and longer-term direct medical costs of care for individuals diagnosed with HIV at CD4 counts <350/mm3 (“late presenters”). We collected and stratified by initial CD4 count all inpatient, outpatient, and drug costs for all newly diagnosed patients accessing HIV care within Southern Alberta from 1/1/1995 to 1/1/2010. 59% of new patients were late presenters. We found significantly higher costs for late presenters, especially inpatient costs, during the first year after accessing care. Direct medical costs remained almost twice as high for late presenters in subsequent years compared to patients presenting with CD4 counts >350/mm3 despite significantly their improved CD4 counts. The sustained high cost for late presenters has implications for recent recommendations for wider routine HIV testing and the earlier initiation of cART. Earlier diagnosis and treatment, while increasing the immediate expenditures within a population, may produce both direct and indirect cost savings in the longer term.
url http://dx.doi.org/10.1155/2012/757135
work_keys_str_mv AT hartmutbkrentz thedirectmedicalcostsoflatepresentation350mm3ofhivinfectionovera15yearperiod
AT mjohngill thedirectmedicalcostsoflatepresentation350mm3ofhivinfectionovera15yearperiod
AT hartmutbkrentz directmedicalcostsoflatepresentation350mm3ofhivinfectionovera15yearperiod
AT mjohngill directmedicalcostsoflatepresentation350mm3ofhivinfectionovera15yearperiod
_version_ 1725593278309466112